Donanemab is an investigational, intravenously administered amyloid beta-directed antibody proposed for the treatment of Alzheimer disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
Jan 20, 2023 | Emerging Technology Report
Donanemab is an investigational, intravenously administered amyloid beta-directed antibody proposed for the treatment of Alzheimer disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
Report Sale Policy: Hayes only sells reports to subscribers and to manufacturers of a health technology that is the subject of the report requested. Individuals requesting reports in response to a payment denial should contact the health insurer involved for details.
Please contact us if you are interested in a Hayes subscription.
Learn more about our Privacy Policy
This site uses cookies. By continuing to use this website, you agree to their use. For details, please review our Privacy Policy